NCT03802903 (Remo-Wax) is a NA clinical trial of Remo-Wax in Cerumen Impaction of Both Ears, sponsored by Orion Corporation, Orion Pharma.

Who is sponsoring NCT03802903?

NCT03802903 is sponsored by Orion Corporation, Orion Pharma.

What drugs are being tested in NCT03802903?

Interventions in NCT03802903: Remo-Wax.

What condition does NCT03802903 study?

NCT03802903 studies Cerumen Impaction of Both Ears.

Is NCT03802903 still recruiting?

NCT03802903 is currently completed. Last updated 15 May 2019.

Last reviewed 2019-05-15 · How we verify

NCT03802903: Remo-Wax

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Remo-Wax for Removal of Impacted Earwax

Completed NA Last updated 15 May 2019

What this trial tests

NA trial testing Remo-Wax in Cerumen Impaction of Both Ears in 52 participants. Completed in 29 April 2019.

Timeline

12 March 2019

Primary endpoint
29 April 2019

29 April 2019

Quick facts

Lead sponsor	Orion Corporation, Orion Pharma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	12 March 2019
Primary completion	29 April 2019
Estimated completion	29 April 2019
Sites	1 location across Lithuania

Drugs / interventions tested

Remo-Wax

Conditions studied

Cerumen Impaction of Both Ears — all drugs for Cerumen Impaction of Both Ears →

Sponsor

Orion Corporation, Orion Pharma — full company profile →

Who can join

1 and older, any sex, with Cerumen Impaction of Both Ears. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates if Remo-Wax ear drops can soften impacted earwax.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Orion Corporation, Orion Pharma trials

Trials by the same sponsor.

NCT06725758 — A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06956495 — Efficacy and Tolerability of Tasipimidine in Sleepless Patients · Phase 2 · completed
NCT05811039 — Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal · NA · completed
NCT05288075 — Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product · Phase 1 · completed
NCT05246046 — Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03802903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Orion Corporation, Orion Pharma
Last refreshed: 15 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03802903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing